Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

78.75USD
23 Feb 2018
Change (% chg)

$1.56 (+2.02%)
Prev Close
$77.19
Open
$77.64
Day's High
$78.86
Day's Low
$77.64
Volume
1,617,212
Avg. Vol
1,149,595
52-wk High
$89.07
52-wk Low
$73.70

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $95,874.12
Shares Outstanding(Mil.): 1,100.99
Dividend: 0.52
Yield (%): 2.39

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Eli Lilly Says CEO David Ricks' FY 2017 Total Compensation Was $15.8 Mln

* ELI LILLY AND CO SAYS CHAIRMAN AND CEO DAVID RICKS' FY 2017 TOTAL COMPENSATION WAS $15.8 MILLION

3:35am IST

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

COPENHAGEN Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity.

21 Feb 2018

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

COPENHAGEN, Feb 21 Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity.

21 Feb 2018

BRIEF-Adocia Files Additional Arbitration Claims Against Eli Lilly & Company​

* ‍ADOCIA FILES ADDITIONAL ARBITRATION CLAIMS AGAINST ELI LILLY & COMPANY​

06 Feb 2018

BRIEF-Eli Lilly plans to deploy around $9 bln of global cash

* SEES 2018 EFFECTIVE TAX RATE OF 18%, DOWN FROM PREVIOUS NON-GAAP EXPECTATION OF 21.5%

31 Jan 2018

U.S. FDA approves new diabetes drug from Merck and Pfizer

A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration said, adding another competitor to a growing class of treatments.

21 Dec 2017

UPDATE 1-U.S. FDA approves new diabetes drug from Merck and Pfizer

Dec 20 A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration said, adding another competitor to a growing class of treatments.

21 Dec 2017

UPDATE 1-Boehringer CFO Menne quits in differences over strategy

FRANKFURT, Dec 15 The chief financial officer of unlisted Boehringer Ingelheim, Simone Menne, will quit Germany's second-largest pharmaceuticals company at year-end after just 16 months in office because of differences over strategy.

15 Dec 2017

BRIEF-NSAV Subsidiary Signs Agreement With Eli Lilly

* NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY

14 Dec 2017

Lilly forecasts 2018 profit largely above estimates

Dec 13 Eli Lilly and Co on Wednesday forecast 2018 earnings largely above analysts' estimates in part due to strong demand for recently launched products such as diabetes drug Trulicity and psoriasis drug Taltz.

13 Dec 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.02 +2.11
Pfizer Inc. (PFE.N) $36.26 +0.52
Novartis AG (NOVN.S) CHF79.38 -0.60
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Abbott Laboratories (ABT.N) $59.71 +0.72
Sanofi SA (SASY.PA) €65.05 +0.16
AstraZeneca plc (AZN.L) 4,752.00 -20.00
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00
Bristol-Myers Squibb Co (BMY.N) $67.95 +2.01
Bristol-Myers Squibb Co (BMYMP.PK) $1,306.55 +216.55

Earnings vs. Estimates